BRPI0506812A - composição base auto-microemulsificável, microemulsão e método de preparação da composição base auto-microemulsificável - Google Patents

composição base auto-microemulsificável, microemulsão e método de preparação da composição base auto-microemulsificável

Info

Publication number
BRPI0506812A
BRPI0506812A BRPI0506812-6A BRPI0506812A BRPI0506812A BR PI0506812 A BRPI0506812 A BR PI0506812A BR PI0506812 A BRPI0506812 A BR PI0506812A BR PI0506812 A BRPI0506812 A BR PI0506812A
Authority
BR
Brazil
Prior art keywords
base composition
microemulsion
self
propofol
composition
Prior art date
Application number
BRPI0506812-6A
Other languages
English (en)
Inventor
Steven B Harris
Nick J Huang
Original Assignee
Bioavailability Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioavailability Inc filed Critical Bioavailability Inc
Publication of BRPI0506812A publication Critical patent/BRPI0506812A/pt
Publication of BRPI0506812B1 publication Critical patent/BRPI0506812B1/pt
Publication of BRPI0506812B8 publication Critical patent/BRPI0506812B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçãO BASE AUTO-MICROEMULSIFICáVEL, MICROEMULSãO E MéTODO DE PREPARAçãO DA COMPOSIçãO BASE AUTOMICROEMULSIFICáVEL. A invenção apresenta um método e uma composição para intensificar as propriedades de dissolução e de biodisponibilidade de propofol (2, 6-diisopropil fenol) para ser utilizado como um anestésico administrado intravenosamente me mamíferos. O método produz uma composição base de emulsão auto-microemulsificável, a qual é utilizada na produção de um preparado de microemulsão à base de água. Em uma composição base de dois (2) componentes preferida, a composição base consiste em um tensoativo. o qual contém polietileno gricol; e propofol líquido. A microemulsão é preparada ao misturar a composição base com um líquido carreador, o que resulta na formação de uma microemulsão que contém concentrações de propofol de até aproximadamente 4% em peso de propofol em relação ao volume de microemulsão. Em uma composição base de quatro (4) componentes, a composição base consiste em: um tensoativo, o qual contém polietileno glicol; propofol líquido; um solvente imiscível em água; e etanol. A microemulsão é preparada ao misturar a composição base com um líquido carreador, o que resulta na formação de uma microemulsão que contém concentrações de propofol de até aproximadamente 10% em peso propofol em relação ao volume da microemulsão.
BRPI0506812A 2004-02-13 2005-02-14 composição base anidra auto-microemulsificável, microemulsão e método de preparação da composição base automicroemulsificável BRPI0506812B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54460404P 2004-02-13 2004-02-13
US60/544,604 2004-02-13
PCT/US2005/004533 WO2005079758A1 (en) 2004-02-13 2005-02-14 A microemulsion preparation of high concentration propofol for anesthetic uses

Publications (3)

Publication Number Publication Date
BRPI0506812A true BRPI0506812A (pt) 2007-06-05
BRPI0506812B1 BRPI0506812B1 (pt) 2020-12-08
BRPI0506812B8 BRPI0506812B8 (pt) 2021-05-25

Family

ID=34886055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506812A BRPI0506812B8 (pt) 2004-02-13 2005-02-14 composição base anidra auto-microemulsificável, microemulsão e método de preparação da composição base automicroemulsificável

Country Status (14)

Country Link
US (2) US8383687B2 (pt)
EP (1) EP1713444A4 (pt)
JP (1) JP5165249B2 (pt)
KR (1) KR20070005617A (pt)
CN (1) CN100479812C (pt)
AU (1) AU2005215517C1 (pt)
BR (1) BRPI0506812B8 (pt)
CA (1) CA2556185C (pt)
EA (1) EA010242B1 (pt)
IL (2) IL177419A (pt)
NZ (1) NZ549016A (pt)
UA (1) UA85578C2 (pt)
WO (1) WO2005079758A1 (pt)
ZA (1) ZA200606947B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0604377A (pt) * 2006-10-27 2008-06-24 Cristalia Prod Quimicos Farm microemulsão óleo/água de propofol estável e pronta-para-uso
WO2008101344A1 (en) * 2007-02-22 2008-08-28 Peter Tomlinson Soluble bioactive lipophilic compounds compositions
AR060926A1 (es) * 2007-05-14 2008-07-23 Ciriaco Quiroga Solucion anestesica transparente de propofol, con baja irritacion venosa.
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CN101411685B (zh) * 2007-10-19 2011-04-20 上海医药工业研究院 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
WO2009059989A1 (de) * 2007-11-06 2009-05-14 B. Braun Melsungen Ag Einen hydrophoben wirkstoff enthaltende wässrige emulsionen
CN101756900B (zh) * 2010-02-25 2012-05-30 谢恬 一种榄香烯微乳
JP4834775B2 (ja) * 2010-03-04 2011-12-14 株式会社 資生堂 日焼け止め用組成物
EP3192509B1 (en) 2014-09-12 2021-03-31 Terumo Kabushiki Kaisha Remifentanil injection
EP3206683A4 (en) 2014-10-16 2018-06-13 The Board of Trustees of the Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
US20180098936A1 (en) * 2015-03-23 2018-04-12 President And Fellows Of Harvard College Methods and compositions for injecting high concentration and/or high viscosity active agent solutions
CN108348451B (zh) 2015-07-01 2023-02-21 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于丙泊酚的递送系统
JP6882321B2 (ja) * 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
KR20190032265A (ko) * 2015-12-09 2019-03-27 포스파제닉스 리미티드 약제학적 제형
CA3045702A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Phosphorylation process of complex alcohols
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
WO2021158575A1 (en) * 2020-02-03 2021-08-12 Natural Extraction Systems, LLC Compositions related to bioactive agents that convert from anions to molecules
WO2021156776A1 (en) 2020-02-06 2021-08-12 Nandkumar Chodankar Simple manufacturing and purification technology for high purity propofol
WO2022182523A1 (en) * 2021-02-26 2022-09-01 Natural Extraction Systems, LLC Compositions related to bioactive agents that convert from anions to molecules

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
GB9514878D0 (en) 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
SE9503143D0 (sv) 1995-09-12 1995-09-12 Astra Ab New preparation
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
BR9907832A (pt) 1998-02-10 2000-10-31 Sicor Inc Composição de propofol contendo sulfito
ATE327735T1 (de) * 1998-04-01 2006-06-15 Jagotec Ag Taxan-mikroemulsionen
AU5574200A (en) * 1999-06-21 2001-01-09 Kuhnil Pharm. Co., Ltd. Anesthetic composition for intravenous injection comprising propofol
KR20010055736A (ko) 1999-12-13 2001-07-04 이규현 프로포폴의 마이크로에멀젼 주사제 조성물
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
WO2001097779A2 (en) * 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
IN188917B (pt) 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
KR100482269B1 (ko) * 2002-10-08 2005-04-14 센츄론(주) 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법
US7326735B2 (en) 2003-04-30 2008-02-05 Parnell Laboratories (Aust) Pty Limited Formulations for anaesthetic use
KR101055736B1 (ko) * 2008-09-30 2011-08-11 엘지전자 주식회사 김치냉장고

Also Published As

Publication number Publication date
EA200601460A1 (ru) 2007-02-27
US8962696B2 (en) 2015-02-24
AU2005215517C1 (en) 2011-04-14
AU2005215517B2 (en) 2009-10-08
CN100479812C (zh) 2009-04-22
US20130131186A1 (en) 2013-05-23
IL177419A0 (en) 2006-12-10
KR20070005617A (ko) 2007-01-10
US8383687B2 (en) 2013-02-26
IL247782A0 (en) 2016-11-30
JP2007522238A (ja) 2007-08-09
UA85578C2 (ru) 2009-02-10
NZ549016A (en) 2012-03-30
EA010242B1 (ru) 2008-06-30
AU2005215517A1 (en) 2005-09-01
JP5165249B2 (ja) 2013-03-21
EP1713444A4 (en) 2012-06-20
BRPI0506812B8 (pt) 2021-05-25
BRPI0506812B1 (pt) 2020-12-08
CN1917858A (zh) 2007-02-21
US20070141090A1 (en) 2007-06-21
CA2556185C (en) 2010-09-21
WO2005079758A1 (en) 2005-09-01
IL177419A (en) 2017-01-31
CA2556185A1 (en) 2005-09-01
EP1713444A1 (en) 2006-10-25
ZA200606947B (en) 2008-01-08

Similar Documents

Publication Publication Date Title
BRPI0506812A (pt) composição base auto-microemulsificável, microemulsão e método de preparação da composição base auto-microemulsificável
ES2525238T3 (es) Método para preparar emulsiones aceite-en-agua a partir de concentrados de geles autoemulsionantes
FI100856B (fi) Menetelmä paikallisesti annettavan ibuprofeenikoostumuksen valmistamis eksi
Engelbrecht et al. Study of the influence of the penetration enhancer isopropyl myristate on the nanostructure of stratum corneum lipid model membranes using neutron diffraction and deuterium labelling
NO20025629D0 (no) Formulering
BRPI1006790B8 (pt) método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico
BRPI0511036A (pt) formulações de solução farmacêuticas contendo 17-aag
BR112018069843A2 (pt) recipiente de porção única, kit, método para obter uma bebida a partir de um recipiente de porção única, e método para obter uma bebida a partir de um kit em partes
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
Harris et al. Targeted and suspect screening of per-and polyfluoroalkyl substances in cosmetics and personal care products
ATE459338T1 (de) Formulierungen für benzimidazolylpyridylether
BR112013024745A8 (pt) Camada de revestimento, e método para formar uma camada de revestimento
Correa et al. On the incorporation of the non-steroidal anti-inflammatory naproxen into cationic O/W microemulsions
Pernomian et al. Cross-talk with β2-adrenoceptors enhances ligand affinity properties from endothelial alpha1D-adrenoceptors that mediates carotid relaxation
BRPI0515517A (pt) processo para a preparação de ciclopentanona, e, uso de uma mistura de hidrocarboneto contendo ciclopenteno
Jbeily et al. Fluorophilicity and lipophilicity of fluorinated rhodamines determined by their partition coefficients in biphasic solvent systems
BR112019028143A2 (pt) mistura de surfactante estabilizado de baixa temperatura para recuperação de óleo intensificada
Arora et al. Interaction of a partially fluorinated heptadecanoic acid with diacyl phosphatidylcholines of varying chain length
Brosnan et al. Hydrocarbon molar water solubility predicts NMDA vs. GABA A receptor modulation
Yener et al. Effect of vehicles on release of meloxicam from various topical formulations
ES2632010T3 (es) Formulaciones acuosas de bisfosfonatos, vitamina D y alcohol bencílico adecuadas para uso subcutáneo o intramuscular
JP6654129B2 (ja) 化粧料用組成物
Manna et al. Composition, functionality and structural correlates of mixed lipid monolayers at air-water interface
BR112012008587A2 (pt) processo de distribuição homogênea para uma composição epóxi com teor de carga elevado
Mariappan et al. Atypical Log D Profile of Rifampicin.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2709 DE 06-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.